Oncoteq

Oncoteq is a clinical-stage biotechnology company specializing in the development of antisense-based immunotherapies for solid tumors and infectious diseases. The company's primary asset is OT-101 (trabedersen), a first-in-class antisense oligonucleotide designed to suppress the expression of Transforming Growth Factor-beta 2 (TGF-beta 2). By inhibiting TGF-beta 2, OT-101 aims to reverse tumor-induced immunosuppression and enhance the efficacy of the immune system against cancers such as glioblastoma and pancreatic carcinoma. Additionally, the company has explored the potential of OT-101 in treating severe respiratory distress associated with COVID-19. Oncoteq was acquired by Mateon Therapeutics in 2020 and continues to advance its clinical programs as a subsidiary.